Document Detail


Clinical experience with rosuvastatin in the management of hyperlipidemia and the reduction of cardiovascular risk.
MedLine Citation:
PMID:  22059787     Owner:  NLM     Status:  In-Data-Review    
Abstract/OtherAbstract:
On the basis of large randomized clinical trials, pharmacological antagonists of HMG-CoA reductase (statins) have become increasingly used in clinical practice for the prevention of cardiovascular disease. Rosuvastatin was developed as a potent statin, which appeared to raise levels of HDL-cholesterol, in addition to marked reductions in levels of LDL-cholesterol. These effects on lipids are associated with a beneficial impact of rosuvastatin on progression of various stages of atherosclerosis and cardiovascular outcomes in clinical trials. The clinical experience of rosuvastatin will be reviewed in this article.
Authors:
Stephen J Nicholls; Kiyoko Uno; Yu Kataoka
Related Documents :
22088767 - Cholesteryl ester transfer protein inhibition to reduce cardiovascular risk: where are ...
20016707 - Effect of chlorella vulgaris intake on cadmium detoxification in rats fed cadmium.
9779417 - Cadmium accumulation in rats treated orally with cadmium chloride for 8 months.
11880177 - Role of oxidative dna damage caused by carbon tetrachloride-induced liver injury -- enh...
19696757 - Higher free fatty acid uptake in visceral than in abdominal subcutaneous fat tissue in ...
18494497 - Crystallization properties and polymorphism of triacylglycerols in goat's milk fat glob...
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Expert review of cardiovascular therapy     Volume:  9     ISSN:  1744-8344     ISO Abbreviation:  Expert Rev Cardiovasc Ther     Publication Date:  2011 Nov 
Date Detail:
Created Date:  2011-11-08     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  101182328     Medline TA:  Expert Rev Cardiovasc Ther     Country:  England    
Other Details:
Languages:  eng     Pagination:  1383-90     Citation Subset:  IM    
Affiliation:
Cardiovascular Medicine and Cell Biology and the Center for Cardiovascular Diagnostics and Prevention, Cleveland Clinic, Cleveland, OH 44195, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Diltiazem in the treatment of hypertension and ischemic heart disease.
Next Document:  Atrial fibrillation catheter ablation in females: same hardware, different findings.